Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: The MYBL2–CCL2 axis promotes tumor progression and resistance to anti-PD-1 therapy in ovarian cancer by inducing immunosuppressive macrophages

Fig. 1

Tumor derived MYBL2 promotes tumor malignancy and macrophage abundance. (A) The expression of MYBL2 was analyzed from single cell sequencing datasets of ovarian cancer by TISCH. (B-C) The representative dataset of ovarian cancer and the MYBL2 expression in all cell types. (D) The MYBL2 mRNA expression in human ovarian surface epitheliums and ovarian tumors. (E) Overall survival (OS) curves based on MYBL2 expression were obtained using the Kaplan–Meier method and analyzed using the log-rank test. (F) Forest plot showing the results of a multivariate analysis of factors associated with OS. Ascites (G), and tumors (H) from orthotopic syngenetic mouse models. (I) Association between the abundance of macrophages and mRNA expression of MYBL2 in OVC. (J-K) Association between the expression of MYBL2 and the expression of CD68 by immunohistochemistry

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us